SCICLONE PHARMACEUTICALS INC 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Sep 29, 2016
Insider Transaction Report
Form 4
CHANG NANCY T
Director
Transactions
- Exercise/Conversion
Common Stock
2016-09-29$5.22/sh+33,333$173,998→ 70,000 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2016-09-29−33,333→ 0 totalExercise: $5.22Exp: 2023-06-17→ Common Stock (33,333 underlying) - Exercise/Conversion
Common Stock
2016-09-29$5.10/sh+7,648$39,005→ 36,667 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2016-09-29−7,648→ 0 totalExercise: $5.10Exp: 2024-06-12→ Common Stock (7,648 underlying)
Footnotes (3)
- [F1]Granted under the Issuer's 2005 Equity Incentive Plan.
- [F2]Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.
- [F3]Shares will become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.